LDS/Medical Tests/GRACILE Syndrome

GRACILE Syndrome

GRACILE syndrome is a fatal metabolic disorder characterized by: fetal growth retardation (GR), aminoaciduria (A), cholestasis (C), iron overload (I), lactacidosis (L), early death (E). GRACILE syndrome is associated with mutations in the BCS1L gene. The BCSL1 gene is located on chromosome 2q35 and encodes proteins essential for the assembly of complex III in the mitochondrial oxidative phosphorylation respiratory chain. As a result, oxidative phosphorylation (energy production) is markedly reduced leading to organ damage, especially in the kidneys and liver. GRACILE syndrome has an autosomal recessive inheritance pattern, with the most common mutation identified as a homozygous c.232A>G mutation in the BCS1L gene. GRACILE syndrome is most prevalent in Finland with 1/50,000 live births being affected. Other ethnicities have a lower incidence with 1/1,500,000 live births impacted. Disease treatment is symptomatic and often ineffective, with the majority of infants dying during the first few days of life. Even with intensive treatment, nearly all infants affected by GRACILE syndrome die within the first four months of life.

  • Carrier screening for at risk individuals and their reproductive partners
  • Establish or confirm diagnosis of GRACILE syndrome for individuals with clinical features suggestive of a mitochondrial respiratory chain disorder
  • Positive: deleterious or predicted deleterious mutations have been detected. Strongly suggests inherited disease, at risk family members may benefit from clinical evaluation and genetic consultation.
  • Variant of unknown significance: Mutation detected which is typically absent in a healthy control population. Current evidence is insufficient to classify mutation as disease causing or benign.
  • Polymorphism detected: Mutation detected which is present in healthy control populations. Mutation is not expected to be disease causing. Familial screening for polymorphisms is not recommended.
  • Negative: No mutations have been identified. Results should be interpreted within the context of other clinical findings; the absence of a mutation does not exclude the possibility of GRACILE syndrome, or positive carrier status. Rare polymorphisms exist and may result in false negative or false positive results.

Negative for mutation analyzed (No mutation detected).

Rare polymorphisms exist that can lead to false negative or false positive results. Results should be interpreted within the context of previous laboratory testing, clinical presentation, and family history. Additional testing is recommended for discordant results/findings.

Targeted variant analysis, deletion/duplication analysis, sequence analysis of entire coding region, Next Generation Sequencing.

Whole blood EDTA or ACD. 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Urine organic acid analysis, serum iron levels, serum ferritin levels, serum pyruvate levels, genetic consultation.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login